局部肾细胞癌中是否存在影响结局所需的最低肉瘤样成分百分比?
研究比较2011年1月至2022年12月加拿大肾癌信息系统数据库中局部肾细胞癌伴或不伴肉瘤样特征患者的结局。共纳入6660例患者(201例伴肉瘤样特征,6459例不伴),155例有肉瘤样成分百分比(%Sarc)数据,中位值10%。加权分析显示肉瘤样特征与转移和死亡风险增加相关,%Sarc>10与%Sarc≤10相比转移和死亡风险增加。
要点
- 肉瘤样特征与局部肾细胞癌患者转移和死亡风险增加相关。
- %Sarc>10与%Sarc≤10相比转移和死亡风险增加。
- %Sarc可能作为辅助治疗风险评估的重要标准,但需进一步研究。
核心结论
- %Sarc>10的患者复发和死亡风险增加,可能受益于更严格的随访,%Sarc可能作为辅助治疗风险评估的重要标准。
研究设计与样本
- 使用加拿大肾癌信息系统数据库识别2011年1月至2022年12月诊断为局部肾细胞癌的患者,纳入pT1-T3、Nx-N0N1、M0期且有肉瘤样状态记录者,共6660例(201例伴肉瘤样特征,6459例不伴),其中155例有%Sarc数据,中位值10%,采用逆概率治疗加权平衡组间,Cox比例风险模型评估肉瘤样状态和%Sarc对无复发生存和总生存的影响。
主要发现
- 加权分析显示,与不伴肉瘤样特征相比,伴肉瘤样特征与转移风险增加和死亡风险增加相关。
- 与%Sarc≤10相比,%Sarc>10与转移风险增加和死亡风险增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival. MATERIAL AND METHODS: The Canadian Kidney Cancer information system database was used to identify patients diagnosed with localised RCC between January 2011 and December 2022. Patients with pT1-T3, n Nx-N0N1, M0 stage and documented sarcomatoid status were included. Patients with sarcomatoid RCC were categorised according to the sarcomatoid component percentage (%Sarc). Inverse probability of treatment weighting scores were used to balance the groups. Cox proportional hazards models were used to assess the impact of sarcomatoid status and %Sarc on recurrence-free and overall survival. RESULTS: A total of 6660 patients (201 with and 6459 without sarcomatoid features) with non-metastatic RCC were included. %Sarc data were available in 155 patients, and the median value was 10%. The weighted analysis revealed that the presence of sarcomatoid features was associated with an increased risk of developing metastasis and increased risk of mortality compared to absence of sarcomatoid features. A %Sarc value >10 was associated with an increased risk of developing metastasis and of mortality compared to a %Sarc value ≤10. CONCLUSIONS: Patients with a %Sarc >10 have an increased risk of recurrence and mortality. These patients may benefit from a more stringent follow-up and %Sarc could represent an important criterion in the risk assessment for adjuvant therapy.
引用
- Soytas M, Dragomir A, Sawaya GB, et al. Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma? BJU Int. 2024. PMID: 39631366. doi:10.1111/bju.16609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。